Who are Pepto-Bismol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Excedrin Extra Strength Pain Reliever, Cytotec, MESALAMINE, Zomiperac, Tylenol Pill, extended postimplantation dual antiplatelet therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bismuth-subsalicylate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pepto-Bismol — Competitive Intelligence Brief

Pepto-Bismol (bismuth subsalicylate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bismuth [EPC]. Area: Other.

marketed Bismuth [EPC] Cyclooxygenase Other Inorganic salt Live · refreshed every 30 min

Target snapshot

Pepto-Bismol (bismuth subsalicylate) — Generic (Procter & Gamble).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pepto-Bismol TARGET	bismuth subsalicylate	Generic (Procter & Gamble)	marketed	Bismuth [EPC]	Cyclooxygenase	1939-01-01
Excedrin Extra Strength Pain Reliever	NSAID	Haleon Us Holdings	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	Cyclooxygenase	2004-01-01
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
MESALAMINE	MESALAMINE		marketed	Aminosalicylate [EPC]	Cyclooxygenase	1987-01-01
Zomiperac	ZOMEPIRAC		marketed	zomepirac	Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase	1980-01-01
Tylenol Pill	Tylenol Pill	Shanghai Zhongshan Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
extended postimplantation dual antiplatelet therapy	extended postimplantation dual antiplatelet therapy	National Institute of Cardiology, Warsaw, Poland	marketed	Antiplatelet therapy combination	Platelet aggregation pathways (cyclooxygenase and P2Y12 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-07-24 — MESALAMINE · 7645801 · Compound · US
2028-06-06 — MESALAMINE · 8217083 · Formulation · US
2028-06-06 — MESALAMINE · 8436051 · Formulation · US
2030-05-01 — MESALAMINE · 8865688 · Method of Use · US

Sponsor landscape (Bismuth [EPC] class)

Generic (Procter & Gamble) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pepto-Bismol — Competitive Intelligence Brief. https://druglandscape.com/ci/bismuth-subsalicylate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab